Bruker (NASDAQ:BRKR) Upgraded by Zacks Research to Strong-Buy Rating

Zacks Research upgraded shares of Bruker (NASDAQ:BRKR) from a hold rating to a strong-buy rating in a research note published on Tuesday,Zacks.com reports.

A number of other analysts have also recently commented on the company. Citigroup lowered their price target on Bruker from $60.00 to $53.00 and set a “neutral” rating for the company in a research report on Wednesday. TD Cowen restated a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Stifel Nicolaus set a $50.00 target price on Bruker in a report on Wednesday. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Bruker presently has a consensus rating of “Moderate Buy” and an average price target of $56.64.

Bruker Trading Up 4.3%

Shares of Bruker stock opened at $52.47 on Tuesday. The firm’s 50 day simple moving average is $58.67 and its two-hundred day simple moving average is $46.73. The firm has a market capitalization of $7.99 billion, a price-to-earnings ratio of -74.96, a PEG ratio of 1.61 and a beta of 1.28. Bruker has a 12-month low of $28.53 and a 12-month high of $65.30. The company has a current ratio of 1.85, a quick ratio of 0.72 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.38 by $0.11. The business had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts predict that Bruker will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, June 22nd. Bruker’s payout ratio is -83.33%.

Institutional Trading of Bruker

Several hedge funds and other institutional investors have recently bought and sold shares of BRKR. Walleye Trading LLC purchased a new position in Bruker during the second quarter valued at approximately $2,702,000. Handelsbanken Fonder AB boosted its position in Bruker by 49.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 54,805 shares of the medical research company’s stock worth $3,298,000 after purchasing an additional 18,165 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Bruker during the 2nd quarter worth approximately $60,000. GAMMA Investing LLC increased its holdings in shares of Bruker by 21.4% during the 2nd quarter. GAMMA Investing LLC now owns 4,755 shares of the medical research company’s stock valued at $286,000 after purchasing an additional 839 shares in the last quarter. Finally, NewEdge Advisors LLC increased its holdings in shares of Bruker by 5,291.2% during the 1st quarter. NewEdge Advisors LLC now owns 1,833 shares of the medical research company’s stock valued at $66,000 after purchasing an additional 1,799 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker News Summary

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported second-quarter adjusted EPS of $0.49, above the $0.38 analyst consensus and up from $0.32 a year earlier. Revenue increased 5.2% year over year to $838.5 million. Bruker Q2 Earnings Beat Estimates
• Positive Sentiment: Zacks Research upgraded BRKR from “hold” to “strong buy,” providing a positive counterpoint to the broader analyst reaction. Zacks.com
• Positive Sentiment: Management highlighted margin strength on the earnings call, while maintaining fiscal 2026 adjusted EPS guidance of $2.10 to $2.15, broadly in line with the $2.12 consensus. Bruker Earnings Call Highlights Margin Strength

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.